RAPP
Rapport Therapeutics, Inc. Common Stock · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +3.6% ·
net new positions +11.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +3 | 25.15M | $1.04B | +5 | −2 |
| Q1 2026 | 69 | +1 | 25.07M | $783.61M | +5 | −4 |
| Q4 2025 | 68 | +1 | 25.43M | $771.51M | +1 | — |
| Q3 2025 | 16 | +4 | 15.68M | $465.84M | +4 | — |
| Q2 2025 | 9 | +1 | 10.01M | $113.83M | +2 | −1 |
| Q1 2025 | 5 | 0 | 1.86M | $18.69M | +1 | −1 |
| Q4 2024 | 5 | 0 | 2.06M | $36.50M | — | — |
| Q3 2024 | 4 | -2 | 1.81M | $36.50M | +1 | −3 |
| Q2 2024 | 6 | — | 2.18M | $50.21M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Fidelity (FMR) ✦ | 5.47M | — | $62.25M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.53M | +42.1% | $17.35M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passive) | 1.22M | — | $13.86M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passive) | 1.11M | — | $12.59M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Geode Capital Management ✦ (passive) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Geode Capital Management ✦ (passive) | 333.16K | +5.5% | $3.79M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passive) | 298.71K | +56.3% | $3.40M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 19.74K | -41.5% | $224,478 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 16.97K | New | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 16.97K | New | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 16.97K | New | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 16.97K | New | $192,971 | 0.0% | New | 1 | SEC ↗ |
| 23 | Renaissance Technologies ✦ | 15.60K | New | $177,372 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| AQR Capital Management | $192,971 | 0.0% |
| Renaissance Technologies | $177,372 | 0.0% |
Exited
| Citadel Advisors | $2.50M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 52.47M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 404 sh · $20,160
Officer, Director · 3.66K sh · $171,837
Officer, Director · 19.50K sh · $936,846
Officer, Director · 5.79K sh · $281,721
Officer, Director · 14.17K sh · $651,492
Officer, Director · 8.37K sh · $391,280
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology